Search Results
Showing Results for metabolic dysfunction-associated steatohepatitis
As we continue advancing the field of endocrinology, I’m excited to spotlight the impactful work being done by the American Association of Clinical Endocrinology (AACE). Our mission is to elevate the practice of clinical endocrinology to improve global health. ...
Article Highlights This study aims to find an effective and affordable biomarker panel for early non-alcoholic fatty liver disease (NAFLD) detection in Indian women with morbid obesity, given the rising prevalence of NAFLD and limited accessibility of ultrasound sonography (USG) ...
Article highlights There is growing clinical importance attributed to the development of metabolic dysfunction-associated steatotic liver disease in people with type 2 diabetes (T2D). Numerous international groups now advocate screening for advanced fibrosis in people with risk factors, such as ...
Hepatic steatosis is the liver manifestation of metabolic syndrome and a common cause of chronic liver disease. Nonalcoholic fatty liver disease (NAFLD) diagnosis relies on the presence of hepatic steatosis, defined as >5% fat accumulation in the liver, as observed ...
Type 2 diabetes (T2D) continues to pose an ever-greater global health challenge, with 1.31 billion individuals predicted to be living with diabetes globally by 2050; the majority of whom will have T2D.1Â Closely linked to T2D is metabolic dysfunction-associated steatotic ...
There has been an exponential increase in the global prevalence of obesity over the past few decades because of adverse lifestyle choices, such as physical inactivity and overconsumption of macronutrients. The obesity pandemic has contributed to more than 50 different disorders ...
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of fatty liver diseases, including non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH).1 NAFLD is associated with metabolic disorders, including obesity, hypertension, dyslipidaemia, type 2 diabetes mellitus (T2DM), hypothyroidism and metabolic syndrome.2 ...
Polycystic ovary syndrome (PCOS) is a very common disease, with an incidence of 5−21% in women during their fertile life (18–45 years of age) worldwide.1 PCOS is clinically diagnosed when two of the three 2003 Rotterdam consensus criteria are met: (i) chronic anovulation ...
Non-alcoholic fatty liver disease (NAFLD), which impacts an estimated 25% of the world’s adult population,1–3 is the principal cause of chronic liver disease globally. NAFLD as a whole represents a pathological spectrum of liver injury, spanning from simple steatosis to ...
Obesity – a chronic, relapsing, progressive disease that is defined by a body mass index (BMI) of ≥27.5 kg/m2 in Asian populations and ≥30.0 kg/m2 in all other populations – is an epidemic that has spread across the world.1 Recent data from ...
Non-alcoholic fatty liver disease (NAFLD) consists of non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). It is unclear which specific patients progress from NAFL to NASH and, ultimately, to cirrhosis. However, there is general consensus that, for those patients who ...
Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome, considered the most common endocrinopathy in women of reproductive age, with a prevalence of 6–8% in premenopausal women.1,2 However, long-term sequelae are extended beyond the reproductive axis, being present from birth to senescence. ...
The prevalence of obesity is rapidly increasing across the world. In India, about 12.6% women and 9.3% men are obese, amounting to more than a 100 million population.1Â Obesity, which was earlier considered to be a growing problem only in metropolitan cities, is ...
Non-alcoholic fatty liver disease (NAFLD), actually the most common cause of chronic liver injury, comprises a disease spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), advanced fibrosis and cirrhosis.1,2 NAFLD is defined as an accumulation of fat, mainly triglycerides (...
Non-alcoholic SteatohepatitisNon-alcoholic fatty liver disease (NAFLD) is a chronic liver condition frequently associated with type 2 diabetes and characterized by insulin resistance and hepatic fat accumulation. Liver fat may range from simple steatosis to severe steatohepatitis with necroinflammation and variable degrees ...
Since the description of Turner syndrome (TS) in 1938, a wealth of information has been added and our current understanding of the syndrome is continuously being broadened. The syndrome affects only females and care must include the close collaboration of several ...
Since non-alcoholic fatty liver disease (NAFLD) was first described in children in the early 1980s by Moran and colleagues,1 a number of case series have been reported. Awareness of the disease has been growing among healthcare providers in the last ...
Compelling evidence suggests an important role for intracellular deposition of fat in non-adipose tissues, e.g. liver, skeletal, and cardiac muscle, and β cells8–14 in the pathogenesis of insulin resistance. Both increased exogenous fat intake (obesity) and excess endogenous fat input (...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
